This is what sets it apart from other vaccines Ahmedabad-based large pharmaceutical company Zydus Cadila, which is also one of the companies developing a new coronavirus vaccine, has applied for emergency approval for its COVID19 vaccine ZyCOVD. ZyCOVD is the COVID19 vaccine developed and manufactured by a major Indian drug company, Zydus Cadila, to fight the novel coronavirus.
The vaccine, which went through clinical trials last July, is likely the third Indian coronavirus vaccine to be approved for use. In addition to being a vaccine made in India, it’s also the first known coronavirus vaccine to use a DNA platform to elicit an adequate immune response.
The DNA technology platform used in the development of the vaccine is the first of its kind in the world and is producing impressive results according to clinical studies and researchers on the COVID19 vaccines that we have with us.
It is also touted as one of the cheapest coronavirus vaccines on the market. Currently, Covishield (Oxford Astrazeneca vaccine) is the most economical.
The company has obtained US interim results from the Pan-India Phase II and III trials. Not only do the developers describe the DNA technology used in the vaccine as safe and effective, but studies have also shown that the vaccine holds a promise of effectiveness. of 67% in reducing symptomatic infections and has a well-established safety and immunogenicity profile.
The data are based on studies with around 28,000 people, 1,000 of whom are children between the ages of 12 and 18.
